Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis: A Phase II Study

NCT06418594 is registered in ClinicalTrials.gov with Beijing 302 Hospital as lead sponsor.

NCT NCT06418594
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06418594 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis: A Phase II Study
Lead sponsor
Beijing 302 Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
October 10, 2024
Completion date
December 31, 2026
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

her2-negative breast cancer brain metastases